Search results
Results from the WOW.Com Content Network
Tinzaparin is an antithrombotic drug in the heparin group. It is a low molecular weight heparin (LMWH) marketed as Innohep worldwide. It has been approved by the U.S. Food and Drug Administration (FDA) for once daily treatment and prophylaxis of deep vein thrombosis (DVT) and pulmonary embolism (PE).
Average molecular weight: heparin is about 15 kDa, and LMWH is about 4.5 kDa. [25] Less frequent subcutaneous dosing than for heparin for postoperative prophylaxis of venous thromboembolism. Once or twice daily subcutaneous injection for treatment of venous thromboembolism and in unstable angina instead of intravenous infusion of high-dose heparin.
Subcutaneous tinzaparin may be given at doses of 175 units of antifactor Xa activity per kg, [13] based on prepregnancy or booking weight at approximately 16 weeks, and not the current weight. [13] While unfractionated heparin is otherwise typically given in an intravenous formulation, this is inconvenient for the prolonged period of ...
Native heparin is a polymer with a molecular weight ranging from 3 to 30 kDa, although the average molecular weight of most commercial heparin preparations is in the range of 12 to 15 kDa. [60] Heparin is a member of the glycosaminoglycan family of carbohydrates (which includes the closely related molecule heparan sulfate ) and consists of a ...
Commonly used low molecular weight heparins are enoxaparin, dalteparin, nadroparin and tinzaparin. [5] [6] In HIT, the platelet count in the blood falls below the normal range, a condition called thrombocytopenia. However, it is generally not low enough to lead to an increased risk of bleeding.
Starter doses of the weight-loss drug Zepbound are now available in single-dose vials, drug manufacturer Eli Lilly announced Tuesday, a move the company says will “significantly” expand supply ...
A 2021 review found that low molecular weight heparin (LMWH) was superior to unfractionated heparin in the initial treatment of venous thromboembolism for people with cancer. [ 3 ] There are medication-based interventions and non-medication-based interventions. [ 4 ]
In single-dose scenarios, the patient's body weight and the drug's recommended dose per kilogram are used to determine a safe one-time dose. If multiple doses of treatment are needed in a day, the physician must take into account information regarding the total amount of the drug which is safe to use in one day, and how that should be broken up ...